Comparative Safety and Efficacy of Dual Antiplatelet Therapy Regimens in Flow Diversion for Intracranial Aneurysms: a Systematic Review and Network Meta-Analysis.

Authors

Marco Frusteri, Anuraag Punukollu, Miguel Gaviria Zapata, Jhoan Sebastián Robledo Arias, Esteban Quiceno

Published in

Clinical neuroradiology. Sep 08, 2026. Epub Sep 08, 2026.

Abstract

Dual antiplatelet therapy is required after flow-diverter treatment of intracranial aneurysms, but the comparative safety and efficacy of clopidogrel-, ticagrelor-, and prasugrel-based regimens remain uncertain. Therefore, the purpose of this study was to compare ischemic, hemorrhagic, functional, and mortality outcomes among different P2Y12 inhibitor-based dual antiplatelet therapy regimens after flow diversion for intracranial aneurysms.
A systematic review and frequentist random-effects network meta-analysis were performed according to PRISMA guidelines. PubMed, Embase, and CENTRAL were searched from inception through February 2026. Eligible studies included randomized and nonrandomized comparative studies evaluating clopidogrel-, ticagrelor-, or prasugrel-based dual antiplatelet therapy after flow-diverter treatment. Outcomes were expressed as odds ratios with 95% confidence intervals relative to clopidogrel. Heterogeneity, consistency, treatment ranking by P‑scores, risk of bias, publication bias, and certainty of evidence were assessed.
Eleven studies including 2267 patients, at least 2285 procedures, and 2502 aneurysms were included. Compared with clopidogrel-based therapy, ticagrelor- and prasugrel-based regimens showed no statistically significant differences in early ischemic or hemorrhagic complications, ischemic or hemorrhagic complications at longest follow-up, or mortality. Ticagrelor was associated with lower odds of a good functional outcome compared with clopidogrel. Prasugrel ranked highest for ischemic outcomes at longest follow-up, hemorrhagic outcomes at longest follow-up, and good functional outcome. Certainty of evidence was low or very low.
Current FD-specific evidence is insufficient to establish superiority, inferiority, or equivalence among clopidogrel-, ticagrelor-, and prasugrel-based DAPT regimens across ischemic, hemorrhagic, functional, and survival outcomes. Because treatment allocation was non-random and alternative regimens were preferentially used in patients with suspected clopidogrel hyporesponsiveness, these findings should not be read as supporting a clopidogrel-first hierarchy; regimen selection is likely to remain guided by local pharmacogenetic testing, and cost considerations pending higher-quality comparative data.

PMID:
42711420
Bibliographic data and abstract were imported from PubMed on 09 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.